The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice

Published on Apr 1, 2020in The Journal of Pathology7.996
· DOI :10.1002/PATH.5406
Paula I. Gonzalez-Ericsson13
Estimated H-index: 13
(VUMC: Vanderbilt University Medical Center),
Elisabeth Specht Stovgaard7
Estimated H-index: 7
(UCPH: University of Copenhagen)
+ 72 AuthorsAnne-Vibeke Lænkholm8
Estimated H-index: 8
Immune checkpoint inhibitor therapies targeting PD-1/PD-L1 are now standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD-L1 expression on immune cells occupying >/=1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab-paclitaxel. However, concerns regarding variability between immunohistochemical PD-L1 assay performance and inter-reader reproducibility have been raised. High tumor-infiltrating lymphocytes (TILs) have also been associated with response to PD-1/PD-L1 inhibitors in patients with breast cancer. TILs can be easily assessed on hematoxylin and eosin stained slides and have shown reliable inter-reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Since TILs and PD-L1 are parts of an immunological spectrum in breast cancer, we propose the systematic implementation of combined PD-L1 and TIL analyses as a more comprehensive immune-oncological biomarker for patient selection for PD-1/PD-L1 inhibition-based therapy in patients with breast cancer. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk-management framework that may help mitigate the risks of suboptimal patient selection for immuno-therapeutic approaches in clinical trials and daily practice based on combined TILs/PD-L1 assessment in breast cancer. This article is protected by copyright. All rights reserved.
Figures & Tables
📖 Papers frequently viewed together
5 Authors (Marius Ilie, ..., Paul Hofman)
#1Nicola Lawson (AstraZeneca)H-Index: 3
#2Carly I Dix (AstraZeneca)H-Index: 2
Last. Craig Barker (AstraZeneca)H-Index: 11
view all 13 authors...
Programmed cell death ligand-1 (PD-L1) expression levels in patient tumor samples have proven clinical utility across various cancer types. Several independently developed PD-L1 immunohistochemical (IHC) predictive assays are commercially available. Published studies using the VENTANA PD-L1 (SP263) Assay, VENTANA PD-L1 (SP142) Assay, Dako PD-L1 IHC 22C3 pharmDx assay, Dako PD-L1 IHC 28-8 pharmDx assay, and laboratory-developed tests utilizing the E1L3N antibody (Cell Signaling Technology), have ...
#1Yuting Liu (Yale University)H-Index: 7
#2Jon Zugazagoitia (Yale University)H-Index: 15
Last. David L. Rimm (Yale University)H-Index: 114
view all 8 authors...
Background: PD-L1 is expressed in tumor cells and immune cells and both have been associated with response to anti-PD-1 axis immunotherapy. Here, we examine the expression of PD-L1 to determine which cell type carries the predictive value of the test. Methods: We measured the expression of PD-L1 in multiple immune cells with two platforms and confocal microscopy on three retrospective Yale NSCLC cohorts (425 non-immunotherapy-treated cases and 62 pembrolizumab/nivolumab/atezolizumab-treated case...
#1Eslie Dennis (Hoffmann-La Roche)H-Index: 2
#2Mark M. KockxH-Index: 62
Last. Ehab E ElGabry (Hoffmann-La Roche)H-Index: 2
view all 6 authors...
BACKGROUND: The VENTANA PD-L1 (SP142) Assay (SP142 assay) is the FDA-approved companion diagnostic for the combination of TECENTRIQ (atezolizumab) and nab-paclitaxel for the treatment of patients with unresectable, locally advanced, or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 - defined as PD-L1 stained tumor-infiltrating immune cells (IC) of any intensity covering ≥ 1 percent of the tumor area. Accurate and reproducible assessment of IC PD-L1 staining with the S...
#1Fahad Shabbir Ahmed (Yale University)H-Index: 7
#2John J. McGuire (Yale University)H-Index: 17
Last. David L. Rimm (Yale University)H-Index: 114
view all 6 authors...
Background: In the IMpassion 130 trial, TNBC patients treated with Atezolizumab and nab-Paclitaxel that showed immune cell expression of PD-L1 showed better overall survival. The goal of this analysis was to assess association between quantitative PD-L1 expression, in various tissue compartments, and pathologic complete response (pCR: ypT0/N0) to neoadjuvant anti-PD-L1 therapy concurrent with nab-paclitaxel (100 mg/m2) x 12 followed by ddAC x 4 chemotherapy in stage I-III triple negative breast ...
#1Sherene Loi (Peter MacCallum Cancer Centre)H-Index: 89
#2Eric P. Winer (Harvard University)H-Index: 152
Last. Roberto Salgado (Peter MacCallum Cancer Centre)H-Index: 59
view all 20 authors...
Background: Several studies show that the presence of TILs has prognostic significance in TNBC, with greater lymphocytic infiltration associated with clinical outcomes. In the phase 2 KEYNOTE-086 study, TIL levels were a surrogate marker of preexisting antitumor immunity and were independent predictors of response to pembrolizumab (pembro) monotherapy. Here, we analyzed the relationship between the presence of TILs and outcomes in the phase 3 KEYNOTE-119 (NCT02555657) study of pembro monotherapy...
#1Jodi M. CarterH-Index: 23
#2Mei Yin PolleyH-Index: 31
Last. Matthew P. GoetzH-Index: 60
view all 10 authors...
#1Emily S. Reisenbichler (Yale University)H-Index: 6
#2Gang Han (TTU: Texas Tech University)H-Index: 23
Last. David L. Rimm (Yale University)H-Index: 114
view all 24 authors...
Background: The IMpassion130 study demonstrated prolonged overall survival when atezolizumab, a PD-L1 inhibitor, was added to nab-paclitaxel in PD-L1 positive patients with advanced triple negative breast cancer (TNBC). Approximately 40% of tumors were PD-L1 positive, utilizing a cutoff of ≥ 1% immune cell (IC) staining with the Ventana SP142 immunohistochemical (IHC) assay. The Food and Drug Administration (FDA) approved this assay as a companion test to determine patient eligibility for atezol...
#1Sandra Martinez-Morilla (Yale University)H-Index: 7
#2John J. McGuire (Yale University)H-Index: 17
Last. David L. Rimm (Yale University)H-Index: 114
view all 21 authors...
Programmed death 1 ligand 1 (PD-L1) Immunohistochemistry (IHC) is the key FDA-approved predictive marker to identify responders to anti-PD1 axis drugs. Multiple PD-L1 IHC assays with various antibodies and cut points have been used in clinical trials across tumor types. Comparative performance characteristics of these assays have been extensively studied qualitatively but not quantitatively. Here we evaluate the use of a standardized PD-L1 Index tissue microarray (TMA) to objectively determine a...
#1Peter Schmid (QMUL: Queen Mary University of London)H-Index: 75
#2Hope S. Rugo (UCSF: University of California, San Francisco)H-Index: 108
Last. IMpassion InvestigatorsH-Index: 1
view all 16 authors...
Summary Background Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim overall survival analysis of the phase 3 IMpassion130 study assessing the efficacy and safety of atezolizumab plus nab-paclitaxel in patients with unresectable, locally advanced or metastatic triple-negative breast cancer. Methods In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 246 academic centre...
#1Emina Torlakovic (U of S: University of Saskatchewan)H-Index: 25
#2Hyun J. Lim (U of S: University of Saskatchewan)H-Index: 23
Last. Ming-Sound Tsao (U of T: University of Toronto)H-Index: 130
view all 32 authors...
Different clones, protocol conditions, instruments, and scoring/readout methods may pose challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic accuracy of using different PD-L1 assays interchangeably for various purposes is unknown. The primary objective of this meta-analysis was to address PD-L1 assay interchangeability based on assay diagnostic accuracy for established clinical uses/purposes. A systematic search of the MEDLINE database using PubMed platform was con...
Cited By55
#1Reilly G. Fankhauser (OHSU: Oregon Health & Science University)H-Index: 4
#2Nicholas A. DePatie (OHSU: Oregon Health & Science University)
Last. Rajan P. KulkarniH-Index: 29
view all 5 authors...
Abstract null null Immunotherapies are a central treatment modality in cancer therapeutics, yet much is still to be determined about their complex mechanisms of action that will allow us to stratify patients based on their likelihood of benefitting from this treatment strategy. Proteomic-based strategies are uniquely poised to investigate these essential questions. Here, we discuss proteomic technologies used for the discovery, validation, and clinical utilization of biomarkers. For each technol...
#1Cong Li (Peking Union Medical College)
#2Shi Qiu (Sichuan University)H-Index: 9
Last. Xun Jin (Sichuan University)
view all 8 authors...
Abstract null null Membrane vesicles, including exosomes and microparticles (MPs), serve to package and transfer the cellular cargo during inter/extracellular communication, which is of great interest in cancer development, especially in the dissemination of signal transduction-associated traits from donor cells to recipient cells. Although increasing evidence suggests that microparticles (MPs) contribute to the development of cancer, their unique characteristics remain to be exploited. Here, we...
#2Carlos H. BarriosH-Index: 60
Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. New targeted therapies such as anti-PD-L1 agents are emerging as an option to treat advanced TNBC. A panel of 6 national experts with an active interest in breast cancer convened online. Panel members had either clinical or pathology experience in breast cancer. The expert...
#1Lucas Grecco Hoffmann (State University of Campinas)
#2Luis Otávio Sarian (State University of Campinas)H-Index: 25
Last. Sophie Françoise Mauricette Derchain (State University of Campinas)H-Index: 28
view all 10 authors...
Herein it was evaluated the impact of PD-L1 immunohistochemical expression and stromal tumor-infiltrating lymphocyte (sTIL) counts in pretreatment needle core biopsy on response to neoadjuvant chemotherapy (NACT) for patients with breast carcinomas (BC). In 127 paired pre- and post-NACT BC specimens, immunohistochemical expression of PD-L1 was evaluated in stroma and in neoplastic cells. In the same samples sTILs were semi-quantified in tumor stroma. Post-NACT specimens were histologically rated...
#1James Wang (UNSW: University of New South Wales)
#2Lois Browne (St George's Hospital)H-Index: 13
Last. Ewan K.A. MillarH-Index: 32
view all 10 authors...
Triple negative breast cancer (TNBC) comprises 10-15% of all breast cancers and has a poor prognosis with a high risk of recurrence within 5 years. PD-L1 is an important biomarker for patient selection for immunotherapy but its cellular expression and co-localization within the tumour immune microenvironment and associated prognostic value is not well defined. We aimed to characterise the phenotypes of immune cells expressing PD-L1 and determine their association with overall survival (OS) and b...
#1Ramin Hosseinzadeh (Tehran University of Medical Sciences)H-Index: 6
Last. Hamed MohammadiH-Index: 25
view all 10 authors...
Immune checkpoint blockade therapy (ICBT) has become a successful cancer treatment approach in the field of cancer immunotherapy. Blockade of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) with monoclonal antibodies have been known as successful examples of cancer immunotherapy in recent years. Although ICBT has been shown to be beneficial in cancers, such benefits have only been seen in a portion of cancer patients. In this regard, enhancing the therapeutic effects of inhibitin...
#1Trine Tramm (Aarhus University Hospital)H-Index: 18
#2H. Vinter (Aarhus University Hospital)H-Index: 7
Last. Jens Overgaard (Aarhus University Hospital)H-Index: 124
view all 6 authors...
Background null The predictive value of tumor-infiltrating lymphocytes (TILs) on the benefit from radiotherapy (RT) remains unclear. Our aim was to investigate the association between TILs and post-mastectomy RT (PMRT) regarding the risk of recurrence and survival in a randomized cohort. null Material and methods null Stromal TILs were histologically estimated in 1011 tumors from high-risk breast cancer (BC) patients from the DBCG82bc trial. Patients were diagnosed between 1982 and 90, treated w...
#1Seri Jeong (Hallym University)H-Index: 9
#2Nuri Lee (Hallym University)H-Index: 3
Last. Wonkeun Song (Hallym University)H-Index: 23
view all 5 authors...
Approximately 20% of breast cancer (BC) patients suffer from distant metastasis. The incidence and prevalence rates of metastatic BC have increased annually. Immune checkpoint inhibitors are an emerging area of treatment, especially for metastatic patients with poor outcomes. Several antibody drugs have been developed and approved for companion testing of the programmed death protine-1 (PD-1) axis. We reviewed currently used laboratory methodologies for assays determining PD-1 axis to provide a ...
#1Sherene Loi (University of Melbourne)H-Index: 89
#2Stefan Michiels (Université Paris-Saclay)H-Index: 69
Last. Roberto Salgado (Peter MacCallum Cancer Centre)H-Index: 59
view all 7 authors...
In 2014, we described a method to quantify percentage of tumor-infiltrating lymphocytes (TILs) on hematoxylin and eosin-stained slides of breast cancer samples using light microscopy that could be performed easily by pathologists with no extra stains. The aim of detailing the method was to facilitate independent research groups replicating our prognostic findings using TIL quantity in early-stage breast cancers. A global working group of breast pathologists was convened to standardize, test repr...
#1Myriam Kossai (French Institute of Health and Medical Research)H-Index: 2
#2Nina Radosevic-Robin (French Institute of Health and Medical Research)H-Index: 22
Last. F. Penault-Llorca (French Institute of Health and Medical Research)H-Index: 29
view all 3 authors...
Therapies that modulate immune response to cancer, such as immune checkpoint inhibitors, began an intense development a few years ago; however, in breast cancer (BC), the results have been relatively disappointing so far. Finding biomarkers for better selection of BC patients for various immunotherapies remains a significant unmet medical need. At present, only tumour tissue programmed death-ligand 1 (PD-L1) and mismatch repair deficiency status are approved as theranostic biomarkers for program...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.